On Tuesday, the U.S. Supreme Court heard arguments in FDA v. Alliance for Hippocratic Medicine, a case that could restrict nationwide access to mifepristone — one of two drugs used in medication abortions.
While the Food and Drug Administration (FDA) approved mifepristone for the medical termination of pregnancy in 2000, a lawsuit filed by the anti-abortion organization Alliance for Hippocratic Medicine in November 2022 challenged the longstanding FDA approval and expansions to access that occurred in 2016 and 2021. The good news is that there appears to be a public consensus that the U.S. Supreme Court will dismiss the case on standing, meaning that the justices won’t agree that the organization that brought the case forward had sufficient legal grounds to do so in the first place.
